Table 1 Demographic and clinical characteristics of hematologic patients with SM bacteremia

Gender, male, No. (%)

31 (56.4)

17 (63.0)

14 (50.0)

0.333

Age, years, median (range)

51 (12–72)

56 (17–72)

48.5 (12–71)

0.049

Positive for SM in sputum culture, No. (%)

14 (25.5)

11 (40.7)

3 (10.7)

0.011

Polymicrobial bacteremia, No. (%)

11 (20.0)

4 (14.8)

7 (25.0)

0.345

Neutropenia, No. (%)

41 (74.5)

24 (88.9)

17 (60.7)

0.016

Hemoglobin < 60 g/L, No. (%)

31 (56.4)

16 (59.3)

15 (53.6)

0.671

Platelet < 50,000/uL, No. (%)

50 (90.9)

25 (92.6)

25 (89.3)

1.000

Fibrinogen< 2 g/L, No. (%)

11 (20.0)

7 (25.9)

4 (14.3)

0.281

PT > 13.5 s, No. (%)

22 (40.0)

14 (51.9)

8 (28.6)

0.078

APTT> 33.5 s, No. (%)

38 (69.1)

21 (77.8)

17 (60.7)

0.171

D-Dimer>700μg/L FEU, No. (%)

45 (81.8)

23 (85.2)

22 (78.6)

0.775

Albumin< 30 g/L, No. (%)

22 (40.0)

12 (44.4)

10 (35.7)

0.509

C-reactive protein≥10 mg/dl, No. (%)

31 (56.4)

17 (68.0)

14 (51.9)

0.236

Procalcitonin > 0.5μg/L, No. (%)

41 (74.5)

25 (92.6)

16 (57.1)

0.003

Hematological diseases

0.544

 AML, No. (%)

31 (56.4)

15 (55.6)

16 (57.1)

 ALL, No. (%)

12 (21.8)

7 (25.9)

5 (17.9)

 NHL, No. (%)

6 (10.9)

3 (11.1)

3 (10.7)

 MDS, No. (%)

1 (1.8)

1 (3.7)

0 (0.0)

 AA, No. (%)

3 (5.5)

0 (0.0)

3 (10.7)

 HLH, No. (%)

2 (3.6)

1 (3.7)

1 (3.6)

Chemotherapy in 30-day, No. (%)

43 (78.2)

21 (77.8)

22 (78.6)

0.943

Inadequate initial antimicrobial treatment, No. (%)

35 (63.6)

16 (59.3)

19 (67.9)

0.508

Central venous catheter, No. (%)

48 (87.3)

25 (92.6)

23 (82.1)

0.449

HSCT, No. (%)

13 (23.6)

6 (22.2)

7 (25.0)

0.808

Prior courses of chemotherapy, No. (%)

0.291

 0

18 (32.7)

7 (25.9)

11 (39.3)

  ≥ 1

37 (67.3)

20 (74.1)

17 (60.7)

Chemotherapy in 30-day, No. (%)

43 (78.2)

21 (77.8)

22 (78.6)

0.943

30-day mortality, No. (%)

37 (67.3)

23 (85.2)

14 (50.0)

0.003